AstraZeneca Halts Lung Cancer Trial of Volrustomig
📊 AZN — Piyasa Yorumu
▼ down · 60%AstraZeneca has announced the discontinuation of a lung cancer trial for volrustomig, a key drug candidate, which may be perceived as a negative signal for the company's R&D pipeline. Technical indicators already present a weak outlook: the RSI at 37.8 is near oversold territory, the MACD is negative and below its signal line, and the price is trading below both the 20-day and 50-day moving averages. The stock has declined 1.76% in the last 24 hours, and this news is likely to add further selling pressure. However, the impact of the news may be limited, as the trial halt decision could already be priced in, and the company's broad portfolio may offset this setback. In the short term, the probability of continued downside movement is moderate.
📊 GOOGL — Piyasa Yorumu
■ neutral · 55%The news is not directly related to GOOGL's core operations, so it is not expected to have a significant impact on the stock. Technical indicators are giving mixed signals: RSI is at 45, in neutral territory; MACD is negative but approaching the signal line; and the price is above the 20-day moving average but below the 50-day moving average. In the short term, a sideways movement is highly likely, with the stock potentially remaining range-bound between the 20-day SMA support and the 50-day SMA resistance. Overall market risk appetite and news flow regarding the technology sector will be more influential in determining GOOGL's direction.